393 related articles for article (PubMed ID: 9918426)
1. Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome.
Hasegawa T; Yoneda M; Nakamura K; Ohnishi K; Harada H; Kyouda T; Yoshida Y; Makino I
J Gastroenterol Hepatol; 1998 Dec; 13(12):1201-6. PubMed ID: 9918426
[TBL] [Abstract][Full Text] [Related]
2. Effects of prolonged (6 months) alpha-glucosidase inhibition on blood glucose control and insulin requirements in patients with insulin-dependent diabetes mellitus.
Dimitriadis G; Karaiskos C; Raptis S
Horm Metab Res; 1986 Apr; 18(4):253-5. PubMed ID: 3519413
[TBL] [Abstract][Full Text] [Related]
3. [Clinical experience with an alpha glucosidase inhibitor (acarbose) in the treatment of non-insulin-dependent diabetes. Multicenter study].
García de los Ríos M; Mujica V; Muñoz S; Durruty P; Larenas G; López MI; Kuzmanic A; Pérez J; Flaskamp R; Cumsille F
Rev Med Chil; 1997 Aug; 125(8):856-62. PubMed ID: 9580485
[TBL] [Abstract][Full Text] [Related]
4. [The effect of alpha-glucosidase inhibitor on burning epigastralgia in dumping syndrome: a case report].
Mimura M; Tsukakubo T; Tsujiguchi N; Hoshikawa T
Masui; 1996 Mar; 45(3):337-9. PubMed ID: 8721135
[TBL] [Abstract][Full Text] [Related]
5. Effects of the alpha-glucosidase inhibitor acarbose on postprandial serum glucose and insulin concentrations in healthy dogs.
Robertson J; Nelson R; Kass P; Neal L
Am J Vet Res; 1999 May; 60(5):541-5. PubMed ID: 10328421
[TBL] [Abstract][Full Text] [Related]
6. alpha-Glucosidase inhibition (acarbose) fails to enhance secretion of glucagon-like peptide 1 (7-36 amide) and to delay gastric emptying in Type 2 diabetic patients.
Hücking K; Kostic Z; Pox C; Ritzel R; Holst JJ; Schmiegel W; Nauck MA
Diabet Med; 2005 Apr; 22(4):470-6. PubMed ID: 15787675
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of postprandial hyperglycemia by acarbose is a promising therapeutic strategy for the treatment of patients with the metabolic syndrome.
Yamagishi S; Nakamura K; Takeuchi M
Med Hypotheses; 2005; 65(1):152-4. PubMed ID: 15893133
[TBL] [Abstract][Full Text] [Related]
8. Effect of lowering postprandial hyperglycemia on insulin secretion in older people with impaired glucose tolerance.
Chang AM; Smith MJ; Bloem CJ; Galecki AT; Halter JB
Am J Physiol Endocrinol Metab; 2004 Nov; 287(5):E906-11. PubMed ID: 15213063
[TBL] [Abstract][Full Text] [Related]
9. The effect of acarbose on insulin sensitivity in subjects with impaired glucose tolerance.
Chiasson JL
Diabet Med; 1996; 13(3 Suppl 2):S23-4. PubMed ID: 8689858
[TBL] [Abstract][Full Text] [Related]
10. Therapeutic potential of alpha-glucosidase-inhibitors.
Fölsch UR
Hepatogastroenterology; 1982 Apr; 29(2):47-8. PubMed ID: 7044933
[No Abstract] [Full Text] [Related]
11. Miglitol suppresses the postprandial increase in interleukin 6 and enhances active glucagon-like peptide 1 secretion in viscerally obese subjects.
Arakawa M; Ebato C; Mita T; Fujitani Y; Shimizu T; Watada H; Kawamori R; Hirose T
Metabolism; 2008 Sep; 57(9):1299-306. PubMed ID: 18702958
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of acarbose as monotherapy in NIDDM patients.
Deerochanawong C; Serirat S; Kornthong P
J Med Assoc Thai; 1996 Feb; 79(2):69-75. PubMed ID: 8868016
[TBL] [Abstract][Full Text] [Related]
13. The mechanism of alpha-glucosidase inhibition in the management of diabetes.
Bischoff H
Clin Invest Med; 1995 Aug; 18(4):303-11. PubMed ID: 8549017
[TBL] [Abstract][Full Text] [Related]
14. Effects of the alpha glucosidase inhibitor acarbose on endothelial function after a mixed meal in newly diagnosed type 2 diabetes.
Pistrosch F; Schaper F; Passauer J; Koehler C; Bornstein SR; Hanefeld M
Horm Metab Res; 2009 Feb; 41(2):104-8. PubMed ID: 19061152
[TBL] [Abstract][Full Text] [Related]
15. Effects of acarbose, an alpha-glucosidase inhibitor (Bay G 5421), on orally loaded glucose, maltose and sucrose and on blood glucose control in non-insulin-dependent diabetics.
Hayakawa T; Noda A; Kondo T; Okumura N
Nagoya J Med Sci; 1985 Jan; 47(1-2):35-41. PubMed ID: 3887176
[No Abstract] [Full Text] [Related]
16. Acarbose, an alpha-glucosidase inhibitor for non-insulin-dependent diabetes.
Welborn TA
Med J Aust; 1998 Jan; 168(2):76-8. PubMed ID: 9469188
[No Abstract] [Full Text] [Related]
17. Acute and long-term effect of alpha-glucosidase inhibitor on dumping syndrome in a patient after a vagotomy and pyloric surgery.
Smith L; Smithers M; Prins J; O'Moore-Sullivan T
ANZ J Surg; 2005 Dec; 75(12):1124-6. PubMed ID: 16398825
[No Abstract] [Full Text] [Related]
18. [Non-insulin-dependent diabetes mellitus associated with nonalcoholic liver cirrhosis: an evaluation of treatment with the intestinal alpha-glucosidase inhibitor acarbose].
Gentile S; Turco S; Guarino G; Oliviero B; Rustici A; Torella R
Ann Ital Med Int; 1999; 14(1):7-14. PubMed ID: 10528419
[TBL] [Abstract][Full Text] [Related]
19. Clinical experience with acarbose as first line therapy in NIDDM.
Fölsch UR
Clin Invest Med; 1995 Aug; 18(4):312-7. PubMed ID: 8549018
[TBL] [Abstract][Full Text] [Related]
20. Effect of inhibition of alpha-glucosidase on age-related glucose intolerance and pancreatic atrophy in rats.
Yamamoto M; Otsuki M
Metabolism; 2006 Apr; 55(4):533-40. PubMed ID: 16546485
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
